trial

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

NCTId NCT01655680
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 432 (actual)
Sponsored by AbbVie
Primary completion 2014-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
432 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2012-05
Primary completion
2014-04
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
ABT-126

Sponsors

AbbVieLead Sponsor

Investigators

1
George Haig, PharmDStudy Director

Sites

61 total
Anaheim, United StatesBellflower, United StatesChino, United StatesCosta Mesa, United StatesEscondido, United StatesGarden Grove, United StatesLa Habra, United StatesNational City, United StatesNorwalk, United StatesOakland, United StatesOceanside, United StatesOrange, United States

Linked catalysts

1
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophr — primary completion2014-04

Facts & assertions

4 sourced
Enrollment
432
Phase
PHASE2
Primary Completion Date
2014-04
Status
COMPLETED
relationships
The graph out of here
drug
ABT-126
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
George Haig, PharmD
person